[1. Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998;134:874–6.10.1001/archderm.134.7.874]Search in Google Scholar
[2. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau J, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011;127(3 Suppl):S60–6.10.1016/j.jaci.2010.11.046]Search in Google Scholar
[3. Descamps V, Ben Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, et al. Prise en charge du drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 2010;137:703–8. [In French]10.1016/j.annder.2010.04.024]Search in Google Scholar
[4. Buck ML. DRESS Syndrome. Pediatr Pharm 2012;18(11).]Search in Google Scholar
[5. Leão RN, Barreto P, Leão RP, Ribeiro JV. Nitrofurantoin: cause of DRESS syndrome. BMJ Case Rep 2013;2013.10.1136/bcr-2013-008991]Search in Google Scholar
[6. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007;156:1083–4.10.1111/j.1365-2133.2007.07807.x]Search in Google Scholar
[7. Choudhary S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol 2013;6(6):31–7.]Search in Google Scholar
[8. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-11.]Search in Google Scholar
[9. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug ypersensitivity syndrome (Drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.10.1016/S1085-5629(96)80038-1]Search in Google Scholar
[10. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome. Part II. Management and therapeutics. J Am Acad Dermatol 2013;68:709-17.]Search in Google Scholar
[11. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010;146:1373–9.10.1001/archdermatol.2010.19820713773]Search in Google Scholar
[12. Descamps V, Ranger-Rogez S. DRESS syndrome. Joint Bone Spine 2014;81:15–21.10.1016/j.jbspin.2013.05.00223816504]Search in Google Scholar
[13. Halink DA, Marijnissen RM, Schut AA, Oude Voshaar RC. Drug reaction with eosinophilia and systemic symptoms induced by carbamazepine: DRESSed to kill. Gen Hosp Psychiatry 2011;33(4):412.e5–8.10.1016/j.genhosppsych.2011.04.01221762844]Search in Google Scholar
[14. Tetart F, Picard D, Janela B. Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features. JAMA Dermatol 2014;150:206-7.10.1001/jamadermatol.2013.669824369386]Search in Google Scholar
[15. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006;155:301-6.10.1111/j.1365-2133.2006.07238.x16882166]Search in Google Scholar
[16. Tohyama M, Hashimoto K, Yasukawa M. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007;157:934-40.10.1111/j.1365-2133.2007.08167.x17854362]Search in Google Scholar
[17. Um SJ, Lee SK, Kim YH, Kim KH, Son CH, Roh MS, et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol 2010;20:556–62.]Search in Google Scholar
[18. Chan JC, Chan HH, Yeung CK. Drug reaction with eosinophilia and systemic symptoms. Hong Kong J Dermatol Venereol 2012;20:163-70.]Search in Google Scholar
[19. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu C, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-80.10.1111/bjd.1250123855313]Search in Google Scholar
[20. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014;14:281-8.10.1038/tpj.2013.4024322785]Search in Google Scholar
[21. Ganeva M, Gancheva T, Lazarova R, Troeva J, Baldaranov I, Vassilev I, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008;47(8):853-60.10.1111/j.1365-4632.2008.03637.x18717872]Search in Google Scholar
[22. Choi HG, Byun J, Moon HC, Yoon JH, Yang KY, Park SC, et al. Allopurinol-induced DRESS syndrome mimicking biliary obstruction. Clin Mol Hepatol 2014;20(1):71–5.10.3350/cmh.2014.20.1.71399233324757661]Search in Google Scholar
[23. Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009;145(1):63–6.10.1001/archdermatol.2008.521295458819153345]Search in Google Scholar
[24. Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 2008;23(3):521–5.10.3346/jkms.2008.23.3.521252654018583892]Search in Google Scholar
[25. Taylor JL, Kulkarni MS, Behringer EC, Yusufali T, Trento A, D’Attellis NP. Minocycline-induced drug reaction with eosinophilia and Systemic symptoms syndrome: myocarditis and multiple organ failure. ICU Dir 2012;3(3):139-43.10.1177/1944451612442687]Search in Google Scholar
[26. Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS. Vemurafenib-induced DRESS. JAMA Dermatol 2013;149:1242-3.10.1001/jamadermatol.2013.527823986488]Search in Google Scholar
[27. Naisbitt DJ, Farrell J, Wong G, Deptta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393–403.10.1067/mai.2003.150712789244]Search in Google Scholar
[28. Su-Yin AN, Tai WW, Olson RK. Lamotrigine-associated reversible severe hepatitis: a case report. J Med Toxicol 2008;4(4):258–60.10.1007/BF03161210355011819031378]Search in Google Scholar
[29. Naveen KN, Ravindra MS, Pai VV, Rai V, Athanikar SB, Girish M. Lamotrigine induced DRESS syndrome. Indian J Pharmacol 2012;44(6):798–800.10.4103/0253-7613.103305352351323248415]Search in Google Scholar
[30. Božić K, Gebauer Bukurov K, Jovanović M, Vujanović Lj, Slankamenac P. Serious rash after prolonged use of lamotrigine - report of four cases. HealthMed 2011;5(2):409-12.]Search in Google Scholar
[31. Ginory A, Chaney-Catchpole M, Demetree JM, Mayol Sabatier LM, Nguyen M. Drug reaction with eosinophilia and systemic symptoms (DRESS) in an adolescent treated with lamotrigine. J Pediatr Pharmacol Ther 2013;18(3):236–40.10.5863/1551-6776-18.3.236377555824052787]Search in Google Scholar
[32. Parri N, Bernardini R, Pucci N, Novembre E, Azzari C, Vierucci A. Drug rash with eosinophilia and systemic symptoms induced by lamotrigine therapy. Int J Immunopathol Pharmacol 2007;20:643-5.10.1177/03946320070200032317880778]Search in Google Scholar
[33. Hussain N, Gosalakkal JA. Lamotrigine rash–a potentially life-threatening complication. Emerg Med J 2007;24:448.10.1136/emj.2006.037754265829817513556]Search in Google Scholar
[34. Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A, Belhadjali H, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol 2009;49:1488-91.10.1177/009127000934498519723672]Search in Google Scholar
[35. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.10.1016/j.amjmed.2011.01.01721592453]Search in Google Scholar
[36. Prevost P, Bédry R, Lacoste D, Ezzedine K, Haramburu F, Milpied B. Hypersensitivity syndrome with olanzapine confirmed by patch tests. Eur J Dermatol 2012;22:126-7.10.1684/ejd.2011.155322157728]Search in Google Scholar
[37. Darlenski R, Kazandjieva J, Tsankov N. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. Clin Dermatol 2015; In press. doi: 10.1016/j.clindermatol.2015.05.00510.1016/j.clindermatol.2015.05.00526321400]Search in Google Scholar
[38. Brajon D, Trechot P, Waton J, Cuny JF, Schmutz JL, Barbaud A. Suspicion of a new cross-reaction between carbamazepine and olanzapine. J Investig Allergol Clin Immunol 2014;24(1):60-1.]Search in Google Scholar
[39. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.10.1038/clpt.1981.1547249508]Search in Google Scholar